Clinical Trials Using Ondansetron Hydrochloride
Clinical trials are research studies that involve people. The clinical trials on this list are studying Ondansetron Hydrochloride. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Carboplatin, Paclitaxel, and Ramucirumab for the Treatment of Stage IV or Recurrent Non-squamous Non-Small Cell Lung Cancer
This phase II trial studies the effect of carboplatin, paclitaxel, and ramucirumab in treating patients with stage IV non-squamous non-small cell lung cancer or non-squamous non-small cell lung cancer that has come back (recurrent) and is growing, spreading, or getting worse after receiving pemetrexed with pembrolizumab as maintenance therapy. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving carboplatin, paclitaxel, and ramucirumab may help in shrinking tumors or delaying tumor growth in patients with non-squamous non-small cell lung cancer.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania
Aprepitant or Fosaprepitant in Combination with Dexamethasone and Ondansetron in Preventing Nausea and Vomiting in Patients with Cancer Receiving Carboplatin-Based Chemotherapy
This phase II trial studies how well aprepitant or fosaprepitant in combination with dexamethasone and ondansetron work in preventing nausea and vomiting in patients with cancer receiving carboplatin-based chemotherapy. Giving aprepitant or fosaprepitant in addition to standard anti-nausea medications such as dexamethasone and ondansetron may help control nausea and vomiting better compared to in dexamethasone and ondansetron alone in patients receiving carboplatin-based chemotherapy.
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Olanzapine with or without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
This phase III trial studies how well olanzapine with or without fosaprepitant dimeglumine works in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine, when given with other drugs, is still effective without using fosaprepitant dimeglumine for controlling nausea and vomiting.
Location: 529 locations